Prolonged alpha-adrenergic stimulation causes changes in leukocyte distribution and lymphocyte apoptosis in the rat.
We have previously shown in the rat model that acutely or chronically increased peripheral catecholamines lead to suppression of lymphocyte responsiveness via alpha(2)-adrenoceptor activation. Here we investigated the effects of alpha-adrenergic treatment on total leukocyte numbers and proportions of leukocyte subsets in peripheral blood and lymphoid tissues. It was found that a 12-h treatment with subcutaneously implanted tablets, one containing norepinephrine (NE) and one propranolol, leads to an increase in total blood leukocyte counts, due to a pronounced increase in granulocytes. In contrast, the numbers of all classes of lymphocytes other than NK cells were decreased. This decrease in blood lymphocytes is apparently not due to redistribution, since in the thymus, spleen, mesenteric and peripheral lymph nodes, the total numbers of lymphocytes were decreased as well, without any changes in subpopulations. Analogous results were obtained with rats adrenalectomized before the catecholamine treatment. Animals that received the alpha-adrenergic treatment displayed significantly more apoptotic cells in the lymphoid organs, as determined by the TUNEL technique. In the spleen, the enhanced rate of apoptosis was confined to the white pulp; red pulp areas exhibited significantly fewer apoptotic cells. Thus, an increased alpha-adrenergic tone in rats led to a general loss of lymphocytes due to lymphocyte directed apoptosis that was independent of glucocorticoids.
Stevenson
J R
JR
Institute for Pathophysiology, Karl-Franzens, University of Graz, Heinrichstrasse 31, A-8010 Graz, Austria.
Westermann
J
J
Liebmann
P M
PM
Hörtner
M
M
Rinner
I
I
Felsner
P
P
Wölfler
A
A
Schauenstein
K
K
D000313:Adrenal Medulla / Q000276:immunology / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000276:immunology; D002395:Catecholamines / Q000276:immunology* / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects* / Q000276:immunology; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D008221:Lymphoid Tissue / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D008297:Male; D015213:Neuroimmunomodulation / Q000187:drug effects* / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D017779:Sympathetic Fibers, Postganglionic / Q000276:immunology / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D011942:Receptors, Adrenergic, alpha; D011433:Propranolol; D009638:Norepinephrine